Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorComín Colet, Josep-
dc.contributor.authorManito Lorite, Nicolás-
dc.contributor.authorSegovia Cubero, Javier-
dc.contributor.authorDelgado, Juan-
dc.contributor.authorGarcía Pinilla, José Manuel-
dc.contributor.authorAlmenar, Luis-
dc.contributor.authorCrespo Leiro, María G.-
dc.contributor.authorSionis, Alessandro-
dc.contributor.authorBlasco, Teresa-
dc.contributor.authorPascual Figal, Domingo-
dc.contributor.authorGonzalez Vilchez, Francisco-
dc.contributor.authorLambert Rodríguez, José Luis-
dc.contributor.authorGrau, Maria-
dc.contributor.authorBruguera, Jordi-
dc.contributor.authorLION- HEART Study Investigators-
dc.description.abstractAims. The LION‐HEART study was a multicentre, double‐blind, randomised, parallel‐group, placebo‐controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with advanced chronic heart failure. Methods and results. Sixty‐nine patients from 12 centres were randomly assigned at a 2:1 ratio to levosimendan or placebo groups, receiving treatment by a 6‐hour intravenous infusion (0.2 μg/kg/min without bolus) every 2 weeks for 12 weeks. The primary endpoint was the effect on serum concentrations of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) throughout the treatment period in comparison with placebo. Secondary endpoints included evaluation of safety, clinical events and health‐related quality of life (HRQoL). The area under the curve (AUC, of the levels of NT‐proBNP over time for patients who received levosimendan was significantly lower than for the placebo group (344 × 103 [95% Confidence Interval (CI) 283 × 103−404 × 103] vs. 535 × 103 [443 × 103−626 × 103], p = 0.003). In comparison with the placebo group, the patients on levosimendan experienced a reduction in the rate of heart failure hospitalisation (hazard ratio 0.25; 95% CI 0.11-0.56; P = 0.001). Patients on levosimendan were less likely to experience a clinically significant decline in HRQoL over time (P = 0.022). Adverse event rates were similar in the two treatment groups. Conclusions. In this small pilot study, intermittent administration of levosimendan to ambulatory patients with advanced systolic heart failure reduced plasma concentrations of NT‐proBNP, worsening of HRQoL and hospitalisation for heart failure. The efficacy and safety of this intervention should be confirmed in larger trials.-
dc.format.extent9 p.-
dc.publisherOxford University Press-
dc.relation.isformatofVersió postprint del document publicat a:
dc.relation.ispartofEuropean Journal of Heart Failure, 2018, vol. 20, num. 7, p. 1128-1136-
dc.rights(c) Comín Colet et al., 2018-
dc.subject.classificationMalalties del cor-
dc.subject.classificationInsuficiència cardíaca-
dc.subject.otherHeart diseases-
dc.subject.otherHeart failure-
dc.titleEfficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
696071.pdf559.01 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.